全部分类
  • Tesevatinib (XL-647)
Tesevatinib (XL-647)的可视化放大

Tesevatinib (XL-647)

A multi-kinase inhibitor

此产品仅用于科学研究,我们不为任何个人用途提供产品和服务

Tesevatinib (XL-647)的二维码
  • 库存: 现货
可选规格
  • 包装
    价格
    促销价
    数量
  • 2mg
    ¥1525.00
    1220.00
    - +
  • 5mg
    ¥3225.00
    2580.00
    - +
  • 10mg
    ¥5175.00
    4140.00
    - +
已选 0 0
金额: ¥0.00
首页 收藏
  • 货号: ajce47746
  • CAS: 781613-23-8
  • 别名: XL-647; EXEL-7647; KD-019
  • 分子式: C24H25Cl2FN4O2
  • 分子量: 491.39
  • 纯度: >98%
  • 溶解度: DMSO : ≥ 30 mg/mL (61.05 mM)
  • 储存: Store at -20°C
  • 库存: 现货

Background

XL647 is a multi-kinase inhibitor (IC50s = 0.3, 16, 1.5, 8.7, and 1.4 nM for EGFR, ErbB2, KDR, FLT4, and EphB4, respectively).1 It is selective for these kinases over a panel of 10 tyrosine kinases and 55 serine/threonine kinases at 10 μM. XL647 inhibits growth of A431 cells expressing wild-type EGFR and H1975 non-small cell lung cancer (NSCLC) cells expressing both the activating mutant EGFRL858R and the drug resistance-associated mutant EGFRT790M (IC50s = 13 and 920 nM, respectively). In vivo, XL647 (10, 30, and 100 mg/kg) inhibits tumor growth and EGFR phosphorylation in an H1975 mouse xenograft model in a dose-dependent manner.


1.Gendreau, S.B., Ventura, R., Keast, P., et al.Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647Clin. Cancer Res.13(12)3713-3723(2007)

Protocol

Cell experiment:

Growth inhibition of H1975 and A431 cells by increasing concentrations of Tesevatinib (XL-647), gefitinib, or erlotinib is determined by seeding 5000 cells per well in 96-well plates. The following day, cells are washed once with low-serum RPMI 1640 (0.1% fetal bovine serum, 1% nonessential amino acids, and 1% penicillin/streptomycin), after which 90 μL of the low-serum RPMI 1640 are added. Test compounds (Tesevatinib (XL-647)) are diluted to 10 times the test concentrations and 10 μL are added to triplicate wells for a 72-h incubation. Cell viability is determined[1].

Animal experiment:

Mice: Tumor-bearing mice are given either Tesevatinib (XL-647), erlotinib, or gefitinib at 100 mg/kg and tumors are harvested 1 to 72 h later. Half an hour before respective time point, EGF (50 μg/mouse) is given via i.v. bolus injection with tumors dissected 30 min later and tumor extracts are prepared by homogenization in 10 volumes of ice-cold lysis buffer. Lysates are clarified by centrifugation and EGFR tyrosine phosphorylation levels are determined by ELISA[1].

参考文献:

[1]. Gendreau SB, et al. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res. 2007 Jun 15;13(12):3713-23.

没有评价数据

温馨提示 ×
商品已成功加入购物车!
购物车共 0 件商品
去购物车结算